Ayesha Jameel, MD
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1013399856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,684 and has fallen 68.8% since, to $836 in 2025.
Across 502 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$858
- Dexcom, Inc.$616
- Amgen$591
- Xeris Pharmaceuticals, Inc.$486
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $1,776 |
| Lilly USA, LLC | 53 | $1,031 |
| AstraZeneca(2 entities) | 53 | $858 |
| Dexcom, Inc. | 32 | $616 |
| Amgen | 31 | $591 |
| Xeris Pharmaceuticals, Inc. | 25 | $486 |
| Sanofi-aventis U.S. LLC | 25 | $429 |
| Boehringer Ingelheim | 25 | $407 |
| AbbVie | 21 | $387 |
| Insulet Corporation | 13 | $244 |
| Bayer | 14 | $218 |
| Zealand Pharma US, Inc. | 13 | $203 |
| Novartis | 8 | $153 |
| Abbott | 8 | $149 |
| IBSA Pharma Inc. | 8 | $146 |
| Medtronic | 8 | $140 |
| Mannkind Corporation | 9 | $139 |
| Recordati_rare_diseases_inc. | 6 | $122 |
| Corcept Therapeutics | 4 | $120 |
| Tandem Diabetes Care, Inc. | 5 | $100 |
| Pfizer | 5 | $100 |
| Merck | 7 | $100 |
| Amarin Pharma, Inc. | 4 | $63 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| RGH Enterprises LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$103
How this compares
$8,832 in reported general payments places this provider in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 261 | $362,007 |
| JardianceEmpagliflozin | 167 | $235,333 |
| MounjaroTirzepatide | 118 | $154,568 |
| TrulicityDulaglutide | 71 | $110,482 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $58,660 |
| FarxigaDapagliflozin Propanediol | 60 | $44,484 |
| JanuviaSitagliptin Phosphate | 33 | $40,292 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $37,263 |
| Novolog FlexpenInsulin Aspart | 54 | $20,436 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $20,240 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $17,782 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $16,008 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $14,794 |
| Humalog Kwikpen U-100Insulin Lispro | 39 | $14,467 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $14,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,776 | $370,076280 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,031 | $265,050189 claims |
| Boehringer IngelheimJardiance | $407 | $235,333167 claims |
| MerckJanuvia, Janumet Xr | $100 | $54,75444 claims |
| AstraZenecaFarxiga | $858 | $44,48460 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $429 | $15,91031 claims |
| AbbVieSynthroid | $387 | $11,025100 claims |
| BayerKerendia | $218 | $8,31413 claims |
| IBSA Pharma Inc.Tirosint | $146 | $5,08523 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $4,408357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Tacoma
- Ronald GrafTacoma$13K
- Gabriela Loperena OropezaTacoma$12K
- Rebecca OverTacoma$6K
- Rani KulkarniTacoma$3K
- Qin OuyangTacoma$2K
- Zhiyu WangTacoma$2K
- Dali ChenTacoma$2K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.